WNT Pathway Mutations in Metachronous Oligometastatic Castration-Sensitive Prostate Cancer
Overview
Authors
Affiliations
Purpose: WNT signaling is a cellular pathway that has been implicated in the development and progression of prostate cancer. Oligometastatic castration-sensitive prostate cancer (omCSPC) represents a unique state of disease in which metastasis-directed therapy (MDT) has demonstrated improvement in progression-free survival. Herein, we investigate the clinical implications of genomic alterations in the WNT signaling cascade in men with omCSPC.
Methods And Materials: We performed an international multi-institutional retrospective study of 277 men with metachronous omCSPC who underwent targeted DNA sequencing of their primary/metastatic tumor. Patients were classified by presence or absence of pathogenic WNT pathway mutations (in the genes APC, RNF43, and CTNNB1). Pearson χ and Mann-Whitney U tests were used to determine differences in clinical factors between genomic strata. Kaplan-Meier survival curves were generated for radiographic progression-free survival and overall survival, stratified according to WNT pathway mutation status.
Results: A pathogenic WNT pathway mutation was detected in 11.2% of patients. Patients with WNT pathway mutations were more likely to have visceral metastases (22.6% vs 2.8%; P < .01) and less likely to have regional lymph node metastases (29.0% vs 50.4%; P = .02). At time of oligometastasis, these patients were treated with MDT alone (33.9%), MDT + limited course of systemic therapy (20.6%), systemic therapy alone (22.4%), or observation (defined as no treatment for ≥6 months after metastatic diagnosis). Multivariable cox regression demonstrated WNT pathway mutations associated with significantly worse overall survival (hazard ratio, 3.87; 95% confidence interval, 1.25-12.00).
Conclusions: Somatic WNT pathway alterations are present in approximately 11% of patients with omCSPC and are associated with an increased likelihood of visceral metastases. Although these patients have a worse natural history, they may benefit from MDT.
Shiota M, Matsubara N, Kato T, Eto M, Osawa T, Abe T J Liq Biopsy. 2025; 7:100282.
PMID: 40027233 PMC: 11863810. DOI: 10.1016/j.jlb.2024.100282.
Wang T, Kim J, Kumar R, Deek R, Stephenson R, Mayer T Transl Cancer Res. 2024; 13(11):6235-6245.
PMID: 39697761 PMC: 11651787. DOI: 10.21037/tcr-24-123.
Wang J, Deek M, Mendes A, Song Y, Shetty A, Bazyar S Radiother Oncol. 2024; 202:110618.
PMID: 39510141 PMC: 11663099. DOI: 10.1016/j.radonc.2024.110618.
Cao Y, Sutera P, Mendes W, Yousefi B, Hrinivich T, Deek M Radiother Oncol. 2024; 199:110443.
PMID: 39094629 PMC: 11405100. DOI: 10.1016/j.radonc.2024.110443.
Metastatic hormone-naïve prostate cancer: a distinct biological entity.
Corres-Mendizabal J, Zacchi F, Martin-Martin N, Mateo J, Carracedo A Trends Cancer. 2024; 10(9):825-841.
PMID: 39048488 PMC: 11397905. DOI: 10.1016/j.trecan.2024.06.005.